HAL (France)
open access
Caractériser et bloquer l'adaptation métabolique induite par la L-asparaginase dans les lymphomes B
La L-asparaginase (L-ASNase) est le seul médicament approuvé dans le traitement des leucémies aiguës lymphoblastiques (LAL) et des lymphomes NK/T-cellules (NKTCL), ciblant l'addiction des cellules tumorales à un acide aminé spécifique. Des travaux antérieurs de l'équipe ont montré son efficacité che
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma#1163370
- Tumor metabolic adaptation induced by L-asparaginase reveals a vulnerability to PARP1/2 inhibitor in B-cell lymphomas#280444
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma#898275
- Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer#852243
- Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers#1292620
Record · ID 1358678
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive